Clinical Trials Directory

Trials / Completed

CompletedNCT05981742

Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
75 (actual)
Sponsor
Al-Rasheed University College · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The goal of this interventional Randomized clinical is to compare the effect of Metformin alone, Cabergoline alone and Metformin and Cabergoline in combination in a sample of Iraqi female patients with polycystic ovary syndrome. The main questions to answer are: 1. What are the effects of the tested regimens on Body mass index (BMI)? 2. What are the effects of the tested regimens on hormonal status? 3. What are the effects of the tested regimens on uterine artery resistive index ? 4. What are the effects of the tested regimens on some inflammatory markers? Participants will be separated into two groups: 1. Group 1 (M): 25 Patients, Received Metformin 500mg per oral twice daily for 90 days duration. 2. Group 2 (D): 25 Patients, Received Dostinex (Pergolin) 0.5 mg per oral (single dose per/week). 3. Group 3 (MD): 25 Pateins, Received metformin 500 mg per oral twice daily for 90 days duration and Dostinex (Pergolin) as 0.5 mg per oral (single dose per/week). Researchers will compare Group 1 (M), Group 2 (D), Group 3 (MD) to observe the effect of the tested treatment regimens on Body Mass Index, Hormonal status, uterine artery resistive index, and some inflammatory markers that are IL-18, Anti-GAD Antibody and GnRH Antibody.

Conditions

Interventions

TypeNameDescription
DRUGMetformin Hydrochloride 500 MGBrand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration
DRUGCabergoline 0.5 MGBrand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
DRUGMetformin Hydrochloride 500 MG + Cabergoline 0.5 MGMetformin Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration Cabergoline Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration

Timeline

Start date
2022-09-21
Primary completion
2023-03-31
Completion
2023-03-31
First posted
2023-08-08
Last updated
2023-08-08

Locations

1 site across 1 country: Iraq

Source: ClinicalTrials.gov record NCT05981742. Inclusion in this directory is not an endorsement.